ENANTIOS is a technology company.
ENANTIOS has raised $2.0M across 1 funding round.
ENANTIOS has raised $2.0M in total across 1 funding round.
Enantios AG is a Swiss biotechnology company that develops advanced measurement platforms and services for the structural analysis of complex biologics and chiral molecules, accelerating drug discovery and quality control in pharmaceuticals.[1][2][3] Their core products include Raman Optical Activity (ROA) spectrometers and "Measurement as a Service," enabling chirality confirmation, conformational analysis, and non-destructive testing without chiral-HPLC, crystallization, or purified standards—serving pharma researchers, CROs, and CMOs in academia and industry.[1][3][4] As a young spin-off, Enantios shows early momentum through participation in major events like BIO International Convention 2025 and CPHI Frankfurt 2025, focusing on applications like antibody-drug conjugates (ADCs) and targeted protein degraders (LDDs).[1][4]
Enantios was founded in December 2022 as a spin-off from ETH Zürich, leveraging proprietary ROA technology developed there for pharmaceutical characterization.[2][3] The team, based in Zurich, Switzerland, is small (1-24 employees) and dedicated to innovation in biotech analytics, led by CEO Dr. Carin Lightner, who represents the company at industry conventions.[1][4] The idea emerged from gaps in traditional tools—despite advances in complex drugs, characterization methods lagged, slowing discovery and raising costs—prompting the creation of compact, user-friendly ROA instruments that fit into glove boxes and simplify workflows.[2][3] Early traction includes offering proof-of-concept services and instruments, with a focus on enabling next-generation medicines through Swiss precision engineering.[2][5]
Enantios stands out in biotech analytics through these key strengths:
Enantios rides the wave of advanced therapeutics like ADCs, LDDs, and biologics, where precise chirality and conformational data are critical yet bottlenecked by outdated tools.[1][3] Timing aligns with surging demand for faster drug development amid rising manufacturing costs and regulatory scrutiny on molecular purity.[2][5] Market forces favoring them include biotech's shift to complex modalities (e.g., non-crystalline biologics) and the need for scalable QC, positioning Enantios to cut discovery timelines and enable quality testing at scale.[3][5] They influence the ecosystem by democratizing high-precision analytics, supporting CROs/CMOs, and fostering pharma-academia ties through ETH origins and events like BIO/CPHI.[1][4]
Enantios is poised for growth by expanding ROA adoption in ADC/LDD pipelines and scaling services to more biologics, potentially partnering with big pharma for in-house integration.[1][3] Trends like AI-driven drug design and sustainable manufacturing will amplify their edge in rapid, green analytics, while global events signal inbound traction.[1][4] Their influence may evolve from niche innovator to standard tool in chiral characterization, humanizing biotech progress through accessible tech that unlocks complex molecules—ultimately speeding therapies that improve lives.[2][3]
ENANTIOS has raised $2.0M in total across 1 funding round.
ENANTIOS's investors include Privilège Ventures, Beat Schillig.
ENANTIOS has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2024 | $2.0M Seed | Privilège Ventures, Beat Schillig |